Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Robelin, Patrick; Tod, Michel; Colomban, Olivier; Lachuer, Joël; Rauglaudre, Gaëtan De; Joly, Florence; Chevalier-Place, Annick; Combe, Pierre; Lortholary, Alain; Hamizi, Salima; Raban, Nadia; Ferron, Gwénaël; Meunier, Jérôme; Berton‐Rigaud, Dominique; Alexandre, Jérôme; Kaminsky, Marie‐Christine; Dubot, Coraline; Léary, Alexandra; Malaurie, E.; You, Benoît

doi:10.1016/j.ygyno.2020.07.021

Cited by 12 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of miR-200b, and miR-200c might be predictive of the effect of treatment with bevacizumab ( Halvorsen et al, 2017 ). Low expression of miR-34a-5p and miR-93-5p were correlated with PFS and OS improvements in OC patients with the treatment of chemotherarpy ± nintedanib ( Robelin et al, 2020 ). As obesity was associated with the level of VEGF, the main target of bevacizumab, adiposity was assessed.…”

Section: Biomarkers Of Anti-angiogenic Therapy In Ocmentioning

confidence: 99%

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

et al. 2023

View full text Add to dashboard Cite

Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization is orchestrated by multiple secreted factors and signaling pathways. The most central proangiogenic signal, vascular endothelial growth factor (VEGF)/VEGFR signaling, is also the primary target of initial clinical anti-angiogenic effort. However, the efficiency of therapy has so far been modest due to the low response rate and rapidly emerging acquiring resistance. This review focused on the current understanding of the in-depth mechanisms of tumor angiogenesis, together with the newest reports of clinical trial outcomes and resistance mechanism of anti-angiogenic agents in OC. We also emphatically summarized and analyzed previously reported biomarkers and predictive models to describe the prospect of precision therapy of anti-angiogenic drugs in OC.

show abstract

Section: Biomarkers Of Anti-angiogenic Therapy In Ocmentioning

confidence: 99%

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Abnormal profiles of circulating miRNAs have been reported in various human diseases including metabolic diseases such as diabetes, cardiovascular disease, and various tumors. Its availability is considered unquestionable, and clinical trials with the therapeutic agents have already been conducted [48][49][50]. Changes of circulating miRNAs have been reported in various hematopoietic malignancies: acute myeloid leukemia [51], acute lymphoblastic leukemia [52,53], chronic myeloid leukemia [54][55][56], chronic lymphocytic leukemia [57,58], and multiple myeloma [59].…”

Section: Discussionmentioning

confidence: 99%

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors

Shibuta

Shimizu

Takada

et al. 2022

Hemato

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are nano-sized particles released from cells and transferring molecules (proteins, lipids and nucleic acids such as mRNA, tRNA and miRNA) to recipient cells. Surface antigens and components are important for the functions as cell-to-cell communication of EVs. Thus, EVs are useful biomarkers for various diseases including leukemias and other types of malignancies. We evaluated whether miRNAs in EVs released from chronic myelogenous leukemia (CML) cells could be used for diagnosis. Microarray analysis of miRNAs in EVs obtained from the culture supernatants of two CML cell lines showed that miR-494 and miR-373-5p were significantly decreased by tyrosine kinase inhibitor for BCR-ABL1. Validation analysis with Taqman-based qRT-PCR of whole serum obtained patients with CML in the chronic phase (n = 5) did not show a significant difference in miR-494 levels compared to the CML accelerated phase and blast crisis patients (n = 5). However, the levels of miR-494 were 2.9-fold higher in the accelerated phase or blast crisis than in the chronic phase (p < 0.05). These results indicate that it is important to measure miR-494 using only EVs rather than whole serum. Our data suggest that EV-miR-494 is a useful biomarker of CML progression and evaluation of response to tyrosine kinase inhibitors.

show abstract

“…At present, some pre-clinical and clinical trials have used miRNA as a target for the early diagnosis and treatment of tumors including pancreatic cancer ( 39 ). However, due to a series of difficulties such as miRNA carrier, miRNA toxicity evaluation, and effectiveness testing, it cannot be used in clinical practice and treatment at present ( 40 ). And metabolic reprogram is necessary for successful metastasis and effective colonization of distant sites ( 41 ).…”

Section: Discussionmentioning

confidence: 99%

MiR-489-3p Reduced Pancreatic Cancer Proliferation and Metastasis By Targeting PKM2 and LDHA Involving Glycolysis

Zhang¹,

He²,

Shen³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

IntroductionMalignant proliferation and metastasis are some of the causes of high mortality in pancreatic cancer. MicroRNAs have been a hot spot in cancer research and are involved in tumor formation and metabolic stress responses. However, the biology function and underlying mechanism of miRNA regulating pancreatic cancer progress is remained uncleared.MethodsRNA-seq analysis the glycolysis associated miRNAs and verified miRNA-489-3p was involving in glycolysis. We used RNA in situ hybridization (ISH) and qRT-PCR to analyze the differential expression of miR-489-3p in pancreatic cancer tissues and adjacent tissues and cell lines. Then the function assay of in vivo and in vitro were used to evaluated the role of miR-489-3p in the proliferation, metastasis and glucose metabolism of pancreatic cancer. Furthermore, dual luciferase reporter and rescue experiments were performed to explore the mechanism underlying in the role of miRNA-489-3p.ResultsWe determined that glycolysis associated miRNA miR-489-3p was downregulated in pancreatic cancer tissues and cell lines. The gain and loos of function experiments confirmed that miR-489-3p could inhibit the proliferation, metastasis and glucose metabolism of pancreatic cancer. Further, we found that miR-489-3p could target regulating LDHA and PKM through the luciferase report experiment. Finally, in vivo experiment confirmed that highly expressed miR-489-3p inhibited the growth of pancreatic cancer.ConclusionIn short, this study identified miR-489-3p as a novel therapy target for pancreatic cancer which was involving in the proliferation, metastasis and glycolysis, but its diagnostic value deserves further study.

show abstract

Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Cited by 12 publications

References 33 publications

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors

MiR-489-3p Reduced Pancreatic Cancer Proliferation and Metastasis By Targeting PKM2 and LDHA Involving Glycolysis

Contact Info

Product

Resources

About